Barclays
TRVI icon

Barclays’s Trevi Therapeutics TRVI Stock Holding History

Barclays’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.3M Buy
1,142,077
+1,088,492
+2,031% +$15.8M ﹤0.01% 1098
2026
Q1 		$639K Sell
53,585
-529,068
-91% -$5.92M ﹤0.01% 3039
2025
Q4 		$7.29M Buy
582,653
+365,768
+169% +$4.23M ﹤0.01% 1930
2025
Q3 		$1.98M Sell
216,885
-298,591
-58% -$2.24M ﹤0.01% 2888
2025
Q2 		$2.82M Buy
515,476
+377,544
+274% +$2.35M ﹤0.01% 2581
2025
Q1 		$868K Sell
137,932
-18,335
-12% -$87.5K ﹤0.01% 3191
2024
Q4 		$644K Buy
156,267
+61,035
+64% +$195K ﹤0.01% 3665
2024
Q3 		$318K Buy
95,232
+61,317
+181% +$182K ﹤0.01% 4050
2024
Q2 		$101K Sell
33,915
-1,280
-4% -$3.56K ﹤0.01% 3899
2024
Q1 		$121K Sell
35,195
-28,602
-45% -$63.8K ﹤0.01% 4360
2023
Q4 		$85.5K Buy
63,797
+50,512
+380% +$76.5K ﹤0.01% 4672
2023
Q3 		$29K Sell
13,285
-767
-5% -$1.73K ﹤0.01% 4069
2023
Q2 		$33.6K Buy
+14,052
New +$35.4K ﹤0.01% 4002
2021
Q4 		– Sell
-100
Closed – – 4738
2021
Q3 		$0 Hold
100
– – ﹤0.01% 5018
2021
Q2 		$0 Buy
+100
New +$225 ﹤0.01% 5082
2020
Q3 		– Sell
-15
Closed – – 5581
2020
Q2 		$0 Buy
+15
New +$53 ﹤0.01% 6232

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Barclays's TRVI Position: Q2 2026 in Review

Barclays increased its Trevi Therapeutics (TRVI) stake by 2,031% in Q2 2026, buying an estimated $15.8M and bringing the position to 1,142,077 shares worth $21.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1098.

Barclays first reported a position in TRVI in Q2 2020 and has held it in 16 quarters since. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Barclays held 1,142,077 shares of Trevi Therapeutics worth $21.3M as of Q2 2026.
  • Barclays bought 1,088,492 Trevi Therapeutics shares in Q2 2026, an estimated $15.8M.
  • Trevi Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1098 holding.
  • Barclays first reported a position in Trevi Therapeutics in Q2 2020 and has held it in 16 quarters since.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.